NUWE NUWELLIS INC

Nuwellis Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

Nuwellis Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

Video webcast now available on-demand

MINNEAPOLIS, July 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., today announced that of Nuwellis, participated in the .

For the event, Mr. Erb dove deeper into his dedication to the Company, how he got to where he is today, and provided insight into why he is passionate about the Company’s programs in development.

The on-demand video webcast is now available on the as well as the  page under the  section of the Company’s website ().

About Nuwellis

Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit or visit us on LinkedIn or X, formerly known as Twitter.

For further information, please contact:

Investor Relations:

Robert Scott

Chief Financial Officer

Media Contact:

Leah McMullen

Director of Communications



EN
23/07/2025

Underlying

NUWENUWELLIS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NUWELLIS INC

 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Participates in the Virtual Investor “What’s Your Story” Summ...

Nuwellis Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference Video webcast now available on-demand MINNEAPOLIS, July 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc., today announced that of Nuwellis, participated in the . For the event, Mr. Erb dove deeper into his dedication to the Company, how he got to where he is today, and provided insight into why he is passionate about the Company’s programs in development. The on-demand video webcast is now available on the as well as the  page under the  section of the Company’s website (). Abou...

16h / 12m 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Regains Compliance with Nasdaq Listing Requirements

Nuwellis Regains Compliance with Nasdaq Listing Requirements MINNEAPOLIS, July 23, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced that it has regained compliance with the Nasdaq Capital Market’s minimum bid price requirement under Listing Rule 5550(a)(2). On July 22, 2025, the Company received formal notice from Nasdaq stating that it has resolved the previously disclosed bid price deficiency. As a result, the hearing previously scheduled with the Nasdaq Hearings ...

16h / 42m 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on Augu...

Nuwellis, Inc. To Report Second Quarter 2025 Financial Results on August 12, 2025 MINNEAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the second quarter 2025 on August 12, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website a...

July 22, 2025 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus o...

Nuwellis Announces Termination of REVERSE-HF Clinical Trial to Focus on Strategic Growth in Outpatient Heart Failure Care WHOWHATWHENWHYNuwellis, Inc.Termination of theREVERSE-HF clinicaltrialJuly 17, 2025To redirect resources towardoutpatient markets where scalableimpact is highest.  MINNEAPOLIS, July 17, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. today announced the termination of its REVERSE-HF clinical trial, a randomized post-market trial evaluating ultrafiltration vs. IV loop diuretic therapy for fluid management in hospitalized heart failure patients. This decision reflects the compan...

July 17, 2025 1 EN
 PRESS RELEASE
Free
NUWE NUWELLIS INC

Nuwellis Secures New U.S. Patent, Strengthening Its Position as a Lead...

Nuwellis Secures New U.S. Patent, Strengthening Its Position as a Leader in Fluid Management Innovation WHOWHATWHEREWHENWHYNuwellis, Inc.Issuance of U.S. Patent No. 12,357,734United States Patent and Trademark OfficeJuly 15, 2025To protect innovations in blood filtering system design and methods that support safe and precise fluid removal during ultrafiltration therapy. MINNEAPOLIS, July 15, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on fluid management solutions, today announced the issuance by the U.S Patent and Trademark Offic...

July 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch